These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group. Tonnel AB; Bons J; Legendre M; Prud'Homme A; Bugnas B; Evano-Celli I; Stuart AM Respir Med; 2000 Jun; 94 Suppl B():S29-34. PubMed ID: 10919683 [TBL] [Abstract][Full Text] [Related]
5. Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life. Edin HM; Andersen LB; Schoaf L; Scott-Wilson CA; Ho SY; Ortega HG Ann Allergy Asthma Immunol; 2009 Apr; 102(4):323-7. PubMed ID: 19441604 [TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. Ayres JG; Millar AB; Sykes AP Respir Med; 2000 Jun; 94 Suppl B():S42-50. PubMed ID: 10919685 [TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International study group. Perruchoud AP; Lundback B; Yigla M; Sykes AP Respir Med; 2000 Jun; 94 Suppl B():S35-41. PubMed ID: 10919684 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. You-Ning L; Humphries M; Du X; Wang L; Jiang J Int J Clin Pract; 2005 Jul; 59(7):754-9. PubMed ID: 15963199 [TBL] [Abstract][Full Text] [Related]
9. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study. Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. Nelson HS; Wolfe JD; Gross G; Greos LS; Baitinger L; Scott C; Dorinsky P Ann Allergy Asthma Immunol; 2003 Sep; 91(3):263-9. PubMed ID: 14533658 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study. Wasserman RL; Baker JW; Kim KT; Blake KV; Scott CA; Wu W; Faris MA; Crim C Ann Allergy Asthma Immunol; 2006 Jun; 96(6):808-18. PubMed ID: 16802768 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study. Qaqundah PY; Sugerman RW; Ceruti E; Maspero JF; Kleha JF; Scott CA; Wu W; Mehta R; Crim C J Pediatr; 2006 Nov; 149(5):663-670. PubMed ID: 17095339 [TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Pearlman DS; Noonan MJ; Tashkin DP; Goldstein MF; Hamedani AG; Kellerman DJ; Schaberg A Ann Allergy Asthma Immunol; 1997 Apr; 78(4):356-62. PubMed ID: 9109702 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. Pearlman DS; Peden D; Condemi JJ; Weinstein S; White M; Baitinger L; Scott C; Ho SY; House K; Dorinsky P J Asthma; 2004; 41(8):797-806. PubMed ID: 15641629 [TBL] [Abstract][Full Text] [Related]
15. A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients. Langley SJ; Sykes AP; Batty EP; Masterson CM; Woodcock A Ann Allergy Asthma Immunol; 2002 May; 88(5):488-93. PubMed ID: 12027070 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. Medley H; Orozco S; Allen A Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247 [TBL] [Abstract][Full Text] [Related]
17. Fluticasone propionate 100 microg bid using a non-CFC propellant, HFA 134a, in asthmatic children. Lyttle B; Gilles J; Panov M; Emeryk A; Wixon C Can Respir J; 2003 Mar; 10(2):103-9. PubMed ID: 12687029 [TBL] [Abstract][Full Text] [Related]
18. Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma. Galant SP; van Bavel J; Finn A; Gross G; Pleskow W; Brown A; Hamedani AG; Harding SM Ann Allergy Asthma Immunol; 1999 Mar; 82(3):273-80. PubMed ID: 10094218 [TBL] [Abstract][Full Text] [Related]
19. Efficacy response of inhaled HFA-albuterol delivered via the breath-actuated Autohaler inhalation device is comparable to dose in patients with asthma. Gross G; Cohen RM; Guy H J Asthma; 2003; 40(5):487-95. PubMed ID: 14529098 [TBL] [Abstract][Full Text] [Related]
20. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients. Dusser D; Vicaut E; Lefrançois G; Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]